Concepts (155)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuroblastoma | 9 | 2020 | 520 | 2.820 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 2 | 2022 | 51 | 1.370 |
Why?
|
| Induction Chemotherapy | 3 | 2020 | 42 | 1.300 |
Why?
|
| Sarcoma | 2 | 2022 | 194 | 1.300 |
Why?
|
| Soft Tissue Neoplasms | 2 | 2022 | 130 | 1.280 |
Why?
|
| Bacterial Infections | 2 | 2020 | 306 | 1.040 |
Why?
|
| Osteosarcoma | 2 | 2024 | 259 | 0.800 |
Why?
|
| Liposarcoma | 1 | 2021 | 21 | 0.750 |
Why?
|
| Bone Neoplasms | 2 | 2024 | 430 | 0.710 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2020 | 29 | 0.690 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2020 | 96 | 0.670 |
Why?
|
| Neutropenia | 2 | 2024 | 201 | 0.670 |
Why?
|
| Rhabdomyosarcoma | 1 | 2022 | 201 | 0.640 |
Why?
|
| Immunotherapy | 3 | 2021 | 662 | 0.640 |
Why?
|
| Chemotherapy-Induced Febrile Neutropenia | 1 | 2017 | 2 | 0.590 |
Why?
|
| Blood Transfusion | 1 | 2019 | 308 | 0.570 |
Why?
|
| Medicaid | 1 | 2019 | 243 | 0.530 |
Why?
|
| Mycoses | 1 | 2017 | 116 | 0.530 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2021 | 530 | 0.530 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 4 | 1 | 2016 | 15 | 0.520 |
Why?
|
| Pyridazines | 1 | 2016 | 51 | 0.520 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2016 | 143 | 0.510 |
Why?
|
| Health Care Costs | 1 | 2019 | 368 | 0.510 |
Why?
|
| Imidazoles | 1 | 2016 | 194 | 0.490 |
Why?
|
| Neovascularization, Pathologic | 1 | 2016 | 240 | 0.480 |
Why?
|
| Infant | 11 | 2022 | 12481 | 0.470 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 422 | 0.470 |
Why?
|
| Neuroimaging | 1 | 2017 | 340 | 0.470 |
Why?
|
| Child | 17 | 2024 | 24528 | 0.470 |
Why?
|
| Molecular Targeted Therapy | 1 | 2017 | 353 | 0.460 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2016 | 208 | 0.460 |
Why?
|
| Length of Stay | 1 | 2019 | 1308 | 0.430 |
Why?
|
| Cell Movement | 1 | 2016 | 835 | 0.410 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2024 | 1127 | 0.380 |
Why?
|
| Child, Preschool | 11 | 2024 | 14085 | 0.380 |
Why?
|
| Neoplasms | 4 | 2022 | 2801 | 0.360 |
Why?
|
| Nephroma, Mesoblastic | 1 | 2010 | 10 | 0.360 |
Why?
|
| Remission, Spontaneous | 1 | 2010 | 69 | 0.350 |
Why?
|
| Adolescent | 10 | 2024 | 19358 | 0.300 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2024 | 1240 | 0.290 |
Why?
|
| Humans | 25 | 2024 | 124398 | 0.290 |
Why?
|
| Prognosis | 3 | 2022 | 4554 | 0.290 |
Why?
|
| Female | 16 | 2024 | 66305 | 0.260 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 3578 | 0.260 |
Why?
|
| Brain | 1 | 2017 | 3003 | 0.250 |
Why?
|
| Young Adult | 5 | 2024 | 8979 | 0.240 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 3137 | 0.240 |
Why?
|
| Ifosfamide | 1 | 2024 | 39 | 0.240 |
Why?
|
| Etoposide | 1 | 2024 | 117 | 0.230 |
Why?
|
| Combined Modality Therapy | 2 | 2019 | 1245 | 0.230 |
Why?
|
| Phenylurea Compounds | 1 | 2024 | 48 | 0.230 |
Why?
|
| Quinolines | 1 | 2024 | 96 | 0.220 |
Why?
|
| Survival Rate | 2 | 2020 | 2020 | 0.220 |
Why?
|
| Male | 12 | 2024 | 61025 | 0.220 |
Why?
|
| Infant, Newborn | 3 | 2022 | 8185 | 0.210 |
Why?
|
| Translocation, Genetic | 2 | 2017 | 356 | 0.200 |
Why?
|
| Biomarkers, Tumor | 2 | 2022 | 1460 | 0.190 |
Why?
|
| Transplantation Conditioning | 2 | 2020 | 323 | 0.180 |
Why?
|
| Lymphoma | 1 | 2024 | 322 | 0.180 |
Why?
|
| Leukemia | 1 | 2024 | 376 | 0.180 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2020 | 38 | 0.180 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2020 | 66 | 0.170 |
Why?
|
| Adult | 7 | 2024 | 29396 | 0.170 |
Why?
|
| Gene Rearrangement | 1 | 2022 | 320 | 0.170 |
Why?
|
| Dactinomycin | 1 | 2019 | 67 | 0.160 |
Why?
|
| Foot Diseases | 1 | 2019 | 24 | 0.160 |
Why?
|
| Thoracic Neoplasms | 1 | 2019 | 36 | 0.160 |
Why?
|
| Thigh | 1 | 2019 | 51 | 0.160 |
Why?
|
| Thoracic Wall | 1 | 2019 | 36 | 0.160 |
Why?
|
| Immunologic Factors | 1 | 2020 | 174 | 0.160 |
Why?
|
| Hematologic Neoplasms | 1 | 2022 | 286 | 0.160 |
Why?
|
| Extremities | 1 | 2019 | 83 | 0.160 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 187 | 0.150 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2022 | 549 | 0.150 |
Why?
|
| Remission Induction | 1 | 2019 | 301 | 0.150 |
Why?
|
| Vincristine | 1 | 2019 | 196 | 0.150 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2019 | 355 | 0.150 |
Why?
|
| Neoplasms, Neuroepithelial | 1 | 2018 | 12 | 0.150 |
Why?
|
| Nuclear Receptor Coactivator 2 | 1 | 2019 | 202 | 0.150 |
Why?
|
| N-Myc Proto-Oncogene Protein | 1 | 2017 | 55 | 0.140 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2024 | 823 | 0.140 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2019 | 212 | 0.140 |
Why?
|
| Repressor Proteins | 1 | 2022 | 820 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2017 | 139 | 0.140 |
Why?
|
| Cyclophosphamide | 1 | 2019 | 421 | 0.140 |
Why?
|
| Gene Amplification | 1 | 2017 | 228 | 0.140 |
Why?
|
| Infant, Premature, Diseases | 1 | 2019 | 242 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2017 | 141 | 0.140 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 1085 | 0.130 |
Why?
|
| Retinal Neoplasms | 1 | 2018 | 100 | 0.130 |
Why?
|
| Wilms Tumor | 1 | 2018 | 113 | 0.130 |
Why?
|
| Epigenesis, Genetic | 1 | 2021 | 675 | 0.130 |
Why?
|
| Neural Crest | 1 | 2016 | 51 | 0.130 |
Why?
|
| Neoplasms, Second Primary | 1 | 2017 | 152 | 0.130 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2016 | 66 | 0.130 |
Why?
|
| Pilot Projects | 1 | 2020 | 1404 | 0.130 |
Why?
|
| Hepatoblastoma | 1 | 2018 | 180 | 0.120 |
Why?
|
| Retrospective Studies | 4 | 2024 | 16234 | 0.120 |
Why?
|
| Mice, Nude | 1 | 2016 | 710 | 0.120 |
Why?
|
| Tumor Cells, Cultured | 1 | 2016 | 1064 | 0.120 |
Why?
|
| Follow-Up Studies | 2 | 2022 | 5107 | 0.120 |
Why?
|
| Antigens, CD | 1 | 2016 | 421 | 0.110 |
Why?
|
| Neoplastic Stem Cells | 1 | 2016 | 300 | 0.110 |
Why?
|
| Sex Factors | 1 | 2017 | 1267 | 0.110 |
Why?
|
| Infant, Premature | 1 | 2019 | 815 | 0.110 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 1333 | 0.110 |
Why?
|
| Blotting, Western | 1 | 2016 | 1108 | 0.110 |
Why?
|
| Work Schedule Tolerance | 1 | 2013 | 39 | 0.110 |
Why?
|
| Risk Factors | 3 | 2017 | 10149 | 0.110 |
Why?
|
| Physician Executives | 1 | 2013 | 40 | 0.110 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2016 | 887 | 0.110 |
Why?
|
| Kidney Neoplasms | 1 | 2018 | 430 | 0.110 |
Why?
|
| Treatment Outcome | 2 | 2020 | 12287 | 0.100 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2013 | 78 | 0.100 |
Why?
|
| Neoplasm Proteins | 1 | 2016 | 669 | 0.100 |
Why?
|
| Perception | 1 | 2013 | 221 | 0.100 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2017 | 538 | 0.100 |
Why?
|
| Incidence | 2 | 2017 | 3086 | 0.100 |
Why?
|
| Data Collection | 1 | 2013 | 383 | 0.100 |
Why?
|
| Fibrosarcoma | 1 | 2010 | 28 | 0.090 |
Why?
|
| Genotype | 1 | 2016 | 2552 | 0.080 |
Why?
|
| Apoptosis | 1 | 2016 | 1789 | 0.080 |
Why?
|
| Prospective Studies | 1 | 2020 | 6089 | 0.080 |
Why?
|
| Cell Proliferation | 1 | 2016 | 2304 | 0.080 |
Why?
|
| Pneumatosis Cystoides Intestinalis | 1 | 2008 | 9 | 0.080 |
Why?
|
| Pediatrics | 2 | 2018 | 1163 | 0.080 |
Why?
|
| Phenotype | 1 | 2017 | 4255 | 0.070 |
Why?
|
| Risk Assessment | 1 | 2017 | 3382 | 0.070 |
Why?
|
| Liver Neoplasms | 1 | 2018 | 1319 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2016 | 2615 | 0.070 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2017 | 1199 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2010 | 2088 | 0.060 |
Why?
|
| Diagnosis, Differential | 1 | 2010 | 1894 | 0.060 |
Why?
|
| Lymphocyte Depletion | 1 | 2024 | 124 | 0.060 |
Why?
|
| United States | 1 | 2019 | 10773 | 0.050 |
Why?
|
| Thrombocytopenia | 1 | 2024 | 226 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2022 | 327 | 0.050 |
Why?
|
| Transplantation, Autologous | 1 | 2020 | 298 | 0.040 |
Why?
|
| Mice | 1 | 2016 | 17725 | 0.040 |
Why?
|
| Animals | 2 | 2016 | 34139 | 0.040 |
Why?
|
| Chromosome Banding | 1 | 2017 | 139 | 0.040 |
Why?
|
| Immunophenotyping | 1 | 2017 | 329 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2017 | 356 | 0.030 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2017 | 138 | 0.030 |
Why?
|
| Bone Marrow | 1 | 2017 | 325 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2024 | 1697 | 0.030 |
Why?
|
| Biopsy | 1 | 2017 | 1237 | 0.030 |
Why?
|
| Workload | 1 | 2013 | 148 | 0.020 |
Why?
|
| Middle Aged | 2 | 2024 | 26459 | 0.020 |
Why?
|
| Education, Medical, Graduate | 1 | 2013 | 514 | 0.020 |
Why?
|
| Radiography, Abdominal | 1 | 2008 | 47 | 0.020 |
Why?
|
| Radiography, Thoracic | 1 | 2008 | 153 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2008 | 426 | 0.020 |
Why?
|
| Aged | 1 | 2024 | 19479 | 0.020 |
Why?
|
| Internship and Residency | 1 | 2013 | 1177 | 0.010 |
Why?
|